17
Participants
Start Date
November 30, 2004
Primary Completion Date
September 30, 2006
Study Completion Date
September 30, 2008
ispinesib
SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks.
British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna
Fraser Valley Cancer Centre at British Columbia Cancer Agency, Surrey
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver
Nova Scotia Cancer Centre at Queen Elizabeth II Health Sciences Centre, Halifax
Margaret and Charles Juravinski Cancer Centre, Hamilton
Toronto Sunnybrook Regional Cancer Centre at Sunnybrook and Women's College Health Sciences Centre, Toronto
Centre Hospitalier de l'Universite de Montreal, Montreal
Lead Sponsor
National Cancer Institute (NCI)
NIH
NCIC Clinical Trials Group
NETWORK